Micro Emerging Active

Designazione Fast Track della FDA di Climb Bio

New narrative with limited coverage — still forming.

Punteggio
0,5
Velocità
▲ 1,0
Articoli
2
Fonti
1

Sentiment Timeline

Event Timeline

Apr 24, 2026
Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran Bullish
Apr 22, 2026
FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a … Neutral

Articoli Correlati

Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran

Yahoo Finance · Apr 24, 2026
Mixed

Cronologia

Ultimo aggiornamentoApr 22, 2026